GLP1R and obesity disorder: Targeting gut hormone receptors to decrease appetite and increase energy expenditure is a major area of interest for the management of body weight (9–11), and the GLP-1 receptor agonist Liraglutide (Saxenda) has recently been approved by the U.S. Food and Drug Administration as a treatment for obesity (12).